

2016 FDA APPROVALS | DRUGS

RESTASIS (CYCLOSPORINE) MULTIDOSE | ALLERGAN

A preservative-free, multidose bottle offering the same preservative-free formulation of Restasis as single-use vials

HUMIRA (ADALIMUMAB) | ABBVIE

Indicated for the treatment of noninfectious intermediate, posterior, and panuveitis. Humira is the first and only FDA-approved non-corticosteroid therapy available for adults for this indication

LUCENTIS (RANIBIZUMAB)

PREFILLED SYRINGE | GENENTECH

The 0.5 mg prefilled syringe is approved to treat people with wet age-related macular degeneration (AMD) and macular edema after retinal vein occlusion (RVO). The Lucentis PFS is the first syringe prefilled with an anti-VEGF medicine FDA-approved to treat two eye conditions

APRIL

JULY

JUNE

OCTOBER

BROMSITE (BROMFENAC)

SUN PHARMA

The first non-steroidal anti-inflammatory drug approved by the FDA to prevent pain and treat inflammation in the eye for patients undergoing cataract surgery

PHOTREXA VISCOUS AND PHOTREXA | AVEDRO

FDA approves corneal collagen cross-linking platform, the KXL System, along with two photoenhancers – Photrex Viscous and Photrex – indicated for the treatment of progressive keratoconus

XIIDRA (LIFITEGRAST) | SHIRE

Twice-daily eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease in adult patients. Approval marks the first prescription pharmacologic treatment option for dry eye disease approved in 13 years